A pilot study of genetic polymorphisms and hemodialysis vascular access thrombosis

Hemodialysis International

Volumn 13, Issue 1, 2009, Pages 19-26

  Brophy, Donald F ^a,b,c   Bukaveckas, Bonny L ^a   Ferreira Gonzalez, Andrea ^a   Archer, Kellie J ^d   Martin, Erika J ^b   Gehr, Todd W B ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b School of Medicine ^*  (United States)

^c Virginia Commonwealth University Medical College of Virginia Campus (VCU MCV)   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic kidney disease; Genetics; Hemodialysis; Vascular access thrombosis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BLOOD CLOTTING FACTOR 5 LEIDEN; CD14 ANTIGEN; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FISH OIL; INSULIN; ORAL CONTRACEPTIVE AGENT; PROTHROMBIN; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; BASE PAIRING; CASE CONTROL STUDY; CATHETER THROMBOSIS; CENTRAL VENOUS CATHETER; CONTROLLED STUDY; DIALYSIS CATHETER; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; RETROSPECTIVE STUDY; TANDEM REPEAT; THROMBOSIS PREVENTION;

ADULT; AGED; CATHETERIZATION, CENTRAL VENOUS; FACTOR V; FEMALE; GENOTYPE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE III; PILOT PROJECTS; POLYMORPHISM, GENETIC; PROTHROMBIN; RENAL DIALYSIS; THROMBOSIS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 59249092238     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2009.00334.x     Document Type: Article

References (31)

1. Smits J, van der Linden J, Blankestijn PJ, Rabelink TJ. Coagulation and haemodialysis access thrombosis. Nephrol Dial Transpl. 2000; 15: 1755-1760.
2. Hayashi R, Huang E, Nissenson AR. Vascular access for hemodialysis. Nat Clin Prac Nephrol. 2006; 2: 504-513.
3. Balwit JM. White Paper: Clinical and Economic Issues in Vascular Access for Hemodialysis. Madison: Ahrens Balwit & Associates; 2002.
4. Girndt M, Heine GH, Ulrich C, Köhler H. DialGene consortium: Gene polymorphism association studies in dialysis: Vascular access. Semin Dial. 2007; 20: 63-67.
5. Shemin D, Lapane KL, Bausserman L, et al. Plasma total homocysteine and hemodialysis access thrombosis: A prospective study. J Am Soc Nephrol. 1999; 10: 1095-1099.
6. Mallamaci F, Bonanno G, Seminara G, et al. Hyperhomocysteinemia and arteriovenous fistula thrombosis in hemodialysis patients. Am J Kidney Dis. 2005; 45: 702-707.
7. Fukasawa M, Matsushita K, Kamiyama M, et al. The methylentetrahydrofolate reductase C677T point mutation is a risk factor for vascular access thrombosis in hemodialysis patients. Am J Kidney Dis. 2003; 41: 637-642.
8. Losito A, Kalidas K, Santoni S, Errico R, Jeffery S. Association of the -159C/T polymorphism of the endotoxin receptor (CD14) with carotid artery disease and cardiovascular mortality in dialysis patients. Blood Purif. 2005; 23: 128-133.
9. Rao M, Guo D, Jaber BL, Tighiouart H, Periera BJ, Balakrishnan VS. Transforming growth factor-beta 1 gene polymorphisms and cardiovascular disease in hemodialysis patients. Kidney Int. 2004; 66: 419-427.
10. Heine GH, Ulrich C, Sester U, Sester M, Köhler H, Girndt M. Transforming growth factor beta1 genotype polymorphisms determine AV fistula patency in hemodialysis patients. Kidney Int. 2003; 64: 1101-1107.
11. Stracke S, Konner K, Köstlin I, et al. Increased expression of TGF-beta 1 and IGF-1 in inflammatory stenotic lesions of hemodialysis fistulas. Kidney Int. 2002; 61: 1011-1019.
12. Basaran O, Atac FB, Karakayali F, et al. Endothelial nitric oxide synthase gene intron 4 (VNTR) polymorphism and vascular access graft thrombosis. J Invest Surg. 2007; 20: 49-53.
13. Rigat B, Hubert C, Alhenc-Gellas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990; 86: 1343-1346.
14. Isbir CS, Akgun S, Yilmaz H, et al. Is there a role of angiotensin-converting enzyme gene polymorphism in the failure of arteriovenous femoral shunts for hemodialysis? Ann Vasc Surg. 2001; 15: 443-446.
15. Sajgure A, Choudhury A, Ahmed Z, Choudhury D. Angiotensin converting enzyme inhibitors maintain polytetrafluoroethylene graft patency. Nephrol Dial Transpl. 2007; 22: 1390-1398.
16. Heine GH, Ulrich C, Köhler H, Girndt M. Is AV fistula patency associated with angiotensin-converting enzyme (ACE) polymorphism and ACE inhibitor intake? Am J Nephrol. 2004; 24: 461-468.
17. Van Rooden CJ, Rosendaal FR, Meinders AE, Van Oostayen JA, Van Der Meer FJ, Huisman MV. The contribution of factor V Leiden and prothrombin G20210A, mutation to the risk of central venous catheter-related thrombosis. Haematologica. 2004; 89: 201-206.
18. Bremer C, Schaefer RM. Heterozygosity for factor V Leiden in a haemodialysis patient with recurrent shunt thrombosis. Nephrol Dial Transpl. 1997; 12: 1775-1776.
19. Atac B, Yakupoglu U, Ozbek N, Ozdemir FN, Bilgin N. Role of genetic mutations in vascular access thrombosis among hemodialysis patients waiting for renal transplantation. Transpl Proc. 2002; 34: 2030-2032.
20. Angchaisuksiri P, Pingsuthiwong S, Sura T, Aryuchai K, Busabaratana M, Atichartakam V. Prevalence of the C766T tetrahydrofolate reductase mutation in Thai patients with deep vein thrombosis. Acta Haematol. 2000; 103: 191-196.
21. Mas VR, Fisher R, Maluf DG, et al. Polymorphisms in cytokines and growth factor genes and their association with acute rejection and recurrence of hepatitis C virus disease in liver transplantation. Clin Genet. 2004; 65: 191-201.
22. Zanchi A, Moczulski DK, Hanna LS, Wantman M, Warram JH, Krolewski AS. Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. Kidney Int. 2000; 57: 405-413.
23. LeVan TD, Von Essen S, Romberger DJ, et al. Polymorphisms in the CD14 gene associated with pulmonary function in farmers. Am J Respir Crit Care Med. 2005; 171: 773-779.
24. Esfahani ST, Cogger EA, Caudill MA. Heterogeneity in the prevalence of methylenetetrahydrofolate reductase gene polymorphisms in women of different ethnic groups. J Am Diet Assoc. 2003; 103: 200-207.
25. McAndrew PE, Brandt JT, Pearl DK, Prior TW. The incidence of the gene for thermolabile methylenetetrahydrofolate reductase in African Americans. Thromb Res. 1996; 83: 195-198.
26. Saran R, Dykstra DM, Wolfe RA, Gillespie B, Held PJ, Young EW. Association between vascular access failure and the use of specific drugs: The dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis. 2002; 40: 1255-1263.
27. Yevzlin AS, Conley EL, Sanchez RJ, Young HN, Becker BN. Vascular access outcomes and medication use: A USRDS study. Semin Dial. 2006; 19: 535-539.
28. Dember LM, Kaufman JS, Beck GJ, et al. Design of the dialysis access consortium (DAC) clopidogrel prevention of early av fistula thrombosis trial. Clin Trials. 2005; 2: 413-422.
29. Dixon BS, Beck GJ, Dember LM. Design of the dialysis access consortium (DAC) aggrenox prevention of access stenosis trial. Clin Trials. 2005; 2: 400-412.
30. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353: 238-248.
31. Huang HY, Thuita L, Strickland P, Hoffman SC, Comstock GW, Helzlsouer KJ. Frequencies of single nucleotide polymorphisms in genes regulating inflammatory responses in a community-based population. BMC Genet. 2007; 8: 7.